APA

Schmitz E. M. H., Benoy-De Keuster S., Meier A. J. L., Scharnhorst V., Traksel R. A. M., Broeren M. A. C. & Derijks L. J. J. (20180719). Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. : Clinical rheumatology.

Chicago

Schmitz E M H, Benoy-De Keuster S, Meier A J L, Scharnhorst V, Traksel R A M, Broeren M A C and Derijks L J J. 20180719. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. : Clinical rheumatology.

Harvard

Schmitz E. M. H., Benoy-De Keuster S., Meier A. J. L., Scharnhorst V., Traksel R. A. M., Broeren M. A. C. and Derijks L. J. J. (20180719). Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. : Clinical rheumatology.

MLA

Schmitz E M H, Benoy-De Keuster S, Meier A J L, Scharnhorst V, Traksel R A M, Broeren M A C and Derijks L J J. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. : Clinical rheumatology. 20180719.